Safety and immunogenicity of PXVX0317, an aluminium hydroxide-adjuvanted chikungunya virus-like particle vaccine: a randomised, double-blind, parallel-group, phase 2 trial - 28/08/22
Summary |
Background |
Chikungunya virus (CHIKV) disease is an ongoing public health threat. We aimed to evaluate the safety and immunogenicity of PXVX0317, an aluminium hydroxide-adjuvanted formulation of a CHIKV virus-like particle (VLP) vaccine.
Methods |
This randomised, double-blind, parallel-group, phase 2 trial was conducted at three clinical trial centres in the USA. Eligible participants were healthy CHIKV-naïve adults aged 18–45 years. Participants were stratified by site and randomly assigned (1:1:1:1:1:1:1:1) to one of the eight vaccination groups using a block size of 16. Group 1 received two doses of unadjuvanted PXVX0317 28 days apart (2 × 20 μg; standard); all other groups received adjuvanted PXVX0317: groups 2–4 received two doses 28 days apart (2 × 6 μg [group 2], 2 × 10 μg [group 3], or 2 × 20 μg [group 4]; standard); group 4 also received a booster dose 18 months after the first active injection (40 μg; standard plus booster); groups 5–7 received two doses 14 days apart (2 × 6 μg [group 5], 2 × 10 μg [group 6], or 2 × 20 μg [group 7]; accelerated); and group 8 received one dose (1 × 40 μg; single). The primary endpoint was the geometric mean titre of anti-CHIKV neutralising antibody on day 57 (28 days after the last vaccination), assessed in the immunogenicity-evaluable population. Additionally, we assessed safety. This trial is registered at ClinicalTrials.gov, NCT03483961.
Findings |
This trial was conducted from April 18, 2018, to Sept 21, 2020; 468 participants were assessed for eligibility. Of these, 415 participants were randomly assigned to eight groups (n=53 in groups 1, 5, and 6; n=52 in groups 2 and 8; n=51 in groups 3 and 7; and n=50 in group 4) and 373 were evaluable for immunogenicity. On day 57, serum neutralising antibody geometric mean titres were 2057·0 (95% CI 1584·8–2670·0) in group 1, 1116·2 (852·5–1461·4; p=0·0015 vs group 1 used as a reference) in group 2, 1465·3 (1119·1–1918·4; p=0·076) in group 3, 2023·8 (1550·5–2641·7; p=0·93) in group 4, 920·1 (710·9–1190·9; p<0·0001) in group 5, 1206·9 (932·4–1562·2; p=0·0045) in group 6, 1562·8 (1204·1–2028·3; p=0·14) in group 7, and 1712·5 (1330·0–2205·0; p=0·32) in group 8. In group 4, a booster dose increased serum neutralising antibody geometric mean titres from 215·7 (95% CI 160·9–289·1) on day 547 to 10 941·1 (7378·0–16 225·1) on day 575. Durability of the immune response (evaluated in groups 1, 4, and 8) was shown up to 2 years. The most common solicited adverse event was pain at the injection site, reported in 12 (23%) of 53 participants who received the unadjuvanted vaccine (group 1) and 111 (31%) of 356 who received the adjuvanted vaccine. No vaccine-related serious adverse events were reported.
Interpretation |
PXVX0317 was well tolerated and induced a robust and durable serum neutralising antibody immune response against CHIKV up to 2 years. A single 40 μg injection of adjuvanted PXVX0317 is being further investigated in phase 3 clinical trials (NCT05072080 and NCT05349617).
Funding |
Emergent BioSolutions.
Le texte complet de cet article est disponible en PDF.Plan
Vol 22 - N° 9
P. 1343-1355 - septembre 2022 Retour au numéro
Article précédent
- Efficacy of RTS,S/AS01E malaria vaccine administered according to different full, fractional, and delayed third or early fourth dose regimens in children aged 5–17 months in Ghana and Kenya: an open-label, phase 2b, randomised controlled trial
- Aaron M Samuels, Daniel Ansong, Simon K Kariuki, Samuel Adjei, Anne Bollaerts, Christian Ockenhouse, Nelli Westercamp, Cynthia K Lee, Lode Schuerman, Dennis K Bii, Lawrence Osei-Tutu, Martina Oneko, Marc Lievens, Maame Anima Attobrah Sarfo, Cecilia Atieno, Danielle Morelle, Ashura Bakari, Tony Sang, Erik Jongert, Maame Fremah Kotoh-Mortty, Kephas Otieno, François Roman, Patrick Boakye Yiadom Buabeng, Yaw Ntiamoah, Opokua Ofori-Anyinam, Tsiri Agbenyega, RTS,S study group, David Sambian, Albert Agordo Dornudo, Lydia Nana Badu, Kwame Akoi, Evans Antwi, Kelvin Onoka, Kevin K’Orimba, Paul Ndaya Oloo, Elizabeth Leakey, Emilia Gvozdenovic, Cristina Cravcenco, Pascale Vandoolaeghe, Johan Vekemans, Karen Ivinson
- Clinical evaluation of the BioFire Global Fever Panel for the identification of malaria, leptospirosis, chikungunya, and dengue from whole blood: a prospective, multicentre, cross-sectional diagnostic accuracy study
- Yukari C Manabe, Joshua Betz, Olivia Jackson, Victor Asoala, Isabel Bazan, Paul W Blair, Aileen Chang, Sarunyou Chusri, John A Crump, Kimberly A Edgel, Dennis J Faix, Stefan Fernandez, Anne T Fox, Jose A Garcia, Max Grogl, Erin A Hansen, Vireak Heang, Stacey L House, Krisada Jongsakul, Michael B Kaburise, Chonticha Klungthong, Mohammed Lamorde, Andrew G Letizia, Ivette Lorenzana, Malen Luy, Vanance P Maro, Christopher N Mores, Christopher A Myers, Abraham R Oduro, Leda Parham, Abigail J Porzucek, Michael Prouty, David S Rabiger, Matthew P Rubach, Crystyan Siles, Maria Silva, Chinaka Ukachu, John N Waitumbi, Cynthia L Phillips, Brian W Jones
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?